Peter P Sordillo1, Lawrence Helson2. 1. SignPath Pharma, Inc., Quakertown, PA, U.S.A. 2. SignPath Pharma, Inc., Quakertown, PA, U.S.A. lhelson@comcast.net.
Abstract
BACKGROUND: The terminal stage of Ebola and other viral diseases is often the onset of a cytokine storm, the massive overproduction of cytokines by the body's immune system. MATERIALS AND METHODS: The actions of curcumin in suppressing cytokine release and cytokine storm are discussed. RESULTS: Curcumin blocks cytokine release, most importantly the key pro-inflammatory cytokines, interleukin-1, interleukin-6 and tumor necrosis factor-α. The suppression of cytokine release by curcumin correlates with clinical improvement in experimental models of disease conditions where a cytokine storm plays a significant role in mortality. CONCLUSION: The use of curcumin should be investigated in patients with Ebola and cytokine storm. Intravenous formulations may allow achievement of therapeutic blood levels of curcumin.
BACKGROUND: The terminal stage of Ebola and other viral diseases is often the onset of a cytokine storm, the massive overproduction of cytokines by the body's immune system. MATERIALS AND METHODS: The actions of curcumin in suppressing cytokine release and cytokine storm are discussed. RESULTS:Curcumin blocks cytokine release, most importantly the key pro-inflammatory cytokines, interleukin-1, interleukin-6 and tumor necrosis factor-α. The suppression of cytokine release by curcumin correlates with clinical improvement in experimental models of disease conditions where a cytokine storm plays a significant role in mortality. CONCLUSION: The use of curcumin should be investigated in patients with Ebola and cytokine storm. Intravenous formulations may allow achievement of therapeutic blood levels of curcumin.
Authors: Todd M Bell; Virginia Espina; Svetlana Senina; Caitlin Woodson; Ashwini Brahms; Brian Carey; Shih-Chao Lin; Lindsay Lundberg; Chelsea Pinkham; Alan Baer; Claudius Mueller; Elizabeth A Chlipala; Faye Sharman; Cynthia de la Fuente; Lance Liotta; Kylene Kehn-Hall Journal: Antiviral Res Date: 2017-04-23 Impact factor: 5.970